Gradalis is dedicated to developing and commercializing “molecular” based personalized therapeutics that are tumor specific, more effective and less toxic than current treatment modalities.

Dr. Steven Burakoff Joins Gradalis SAB Appointment of Dr. Steven Burakoff to the SAB
iC3 Life Science Summit Press Release Gradalis to Participate in 2nd Annual iC3 Life Science Summit Hosted By BioNorthTX
Bio Investor Forum Press Release Gradalis to Take Part in BIO Investor Forum in San Francisco
SAB Formation Press Release Sir Marc Feldmann to Chair Gradalis Scientific Advisory Board